| Document |
Document Title |
|
WO/2014/061693A1 |
The purpose of the present invention is to provide a novel compound that has an ACC2 inhibitory activity. Also provided is a medicinal composition containing the compound. A compound represented by formula (I) or a pharmaceutically accep...
|
|
WO/2014/055548A1 |
Disclosed are pyridinone compounds, method for preparing these compounds, and methods for treating fibrotic disorders.
|
|
WO/2014/036956A1 |
The present invention provides crystal forms of the compound of (3R,4S)-4-(4-hydroxyphenyl)-3-[3-(4-fluorophenyl)-4-hydroxyb
ut-2(Z)-enyl]-1-(4-fluorophenyl)-2-azetidinone (formula A). The crystal forms can be characterized by X-ray powd...
|
|
WO/2014/012495A1 |
Disclosed are a chiral α-methylene-β-lactam compound and a preparation method and an application thereof. An asymmetric allyl amination reaction of catalyzing a class of Morita-Baylis-Hillman adducts by using a complex formed by a chir...
|
|
WO/2014/012372A1 |
A process for the production of ezetimibe and intermediates used in said process are disclosed. A kind of Morita-Baylis-Hillman adduct can be altered to carboxylic acid derivatives of β-arylamino α-methylene with high activity and sele...
|
|
WO/2014/008197A1 |
Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by disregulation of a f...
|
|
WO/2013/186326A1 |
The present invention relates to a process for preparing -aminobutyryl substituted 5,6,7,8-tetrahydro[1,4]diazolo[4,3-α]pyrazin-7-yl compounds.
|
|
WO/2013/186159A1 |
The invention provides novel compounds having the general formula (I), wherein R1, R2, Y and W are as described herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2013/160418A1 |
The present invention is directed to novel retinoid-related orphan receptor gamma (RORγ) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammator...
|
|
WO/2013/161851A1 |
The present invention pertains to a benzamide derivative represented by formula (I), or a pharmaceutically acceptable salt thereof.
|
|
WO/2013/163239A1 |
Methods for the synthesis of lactams are presented whereby a carboxylic acid of the formula HOOC------OR---NH-LG, wherein OR is an organic moiety and LG is a leaving group, is reacted with an acid, such as an organic acid, in particular ...
|
|
WO/2013/126381A1 |
The present invention relates to novel phenoxy-azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingo-sine-l-phosphate receptors.
|
|
WO/2013/120448A1 |
Disclosed is a new method for preparing a methyl substitute of a linezolid intermediate, (S)-2-((3-(3-Fluoro-4-Morpholine phenyl)-2-oxy-5-oxazoline)) (I), wherein the intermediate (I) is obtained by the cyclisation of a 3-Fluoro-4-morpho...
|
|
WO/2013/113915A1 |
This invention relates to novel processes for synthesizing N-(4-cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester and to the compound of formula I and other intermediates that are used in such processes.
|
|
WO/2013/102242A1 |
The present invention relates to heterocyclic compounds useful for antagonising angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to pyrrolidine and azetidine compounds, compositions containing them and their ...
|
|
WO/2013/102826A1 |
The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new...
|
|
WO/2013/098373A1 |
The invention relates to new azetidine derivatives of the formula (I) to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.
|
|
WO/2013/098375A1 |
The invention relates to new azetidine derivatives of the formula (I), to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.
|
|
WO/2013/092778A2 |
Compounds according to formula (I) or formula (II) wherein R1 and R2, independently from each other, are chosen among hydrocarbons having from 1 carbon atom up to 30 carbon atoms, with the proviso that at least one of R1 and R2 are chose...
|
|
WO/2013/088315A1 |
The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new...
|
|
WO/2013/068785A1 |
The invention relates to indanone/indandione derivatives and heterocyclic analogs of Formula (I) wherein Ar1, A, B, L1, Y, Z, and (R1)n n are as described in the description; to pharmaceutically acceptable salts thereof, and to the use o...
|
|
WO/2013/057320A1 |
The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a n...
|
|
WO/2013/059651A1 |
A compound having the formula (I) wherein X is S, SO or SO2; one of R1, R2, and R3 is O and the others of R1, R2 and R3 are independently, the same or different, CH2, or CR13 wherein, R13 is an alkyl group, an alkenyl group, an alkynyl g...
|
|
WO/2013/047701A1 |
A compound represented by general formula (I-1) (where all of the symbols are as defined in the specification) has a powerful human S1P2 antagonist action as a result of the introduction of two cyclic groups, particularly phenoxy groups,...
|
|
WO/2013/041480A1 |
The present invention relates to novel amide compounds of Formula (I), and their use as anti-tumoral and pro-apoptotic agents. The invention includes the use of such compounds in medicine, in relation to cancer disease as well as other d...
|
|
WO/2013/036015A2 |
The present invention relates to an azetidine derivative, to pharmaceutically acceptable salts thereof, to an antidepressant, and to a composition including same, for preventing or treating depression or psychiatric disorders. The azetid...
|
|
WO/2013/017548A1 |
Disclosed are compounds of formula (I): wherein one of A and B is the group:(II) wherein R1 is selected from H and OCH3, and the other is the group:(III) wherein R2 is selected from H, OH, NO2, NH2; R3 is selected from OH and NH2;15 the ...
|
|
WO/2013/013505A1 |
The present invention relates to a 9-aminomethyl substituted tetracycline compound represented by general formula (I), pharmaceutically acceptable salts, solvates or isomers thereof, wherein R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R7, R8, ...
|
|
WO/2013/014604A1 |
Provided is a crystalline composition comprising a mixture of a compound of formula 1 (Ezetimibe) and proline or proline derivatives, or a hydrate/solvate thereof, as well as a process for obtaining the same. And a process for the purifi...
|
|
WO/2013/013504A1 |
The invention belongs to the medicinal technical field, and in particular relates to a tigecycline derivative of general formula (I), a pharmaceutically acceptable salt, precursor drug, solvate or isomer thereof, wherein R2a, R2b, R3, R4...
|
|
WO/2013/008002A1 |
There is provided a compound which is (a) a pyrimidine sulfonamide of formula (I) or (b) a pharmaceutically acceptable salt thereof, crystalline forms of the compound, processes for obtaining the compound, pharmaceutical intermediates us...
|
|
WO/2012/175962A1 |
Provided are compounds for use in a method of treatment of a subject who has a lesion or a tumour in which p53 carries a Y220C mutation, in which the compound is selected from compounds of the following formula (I), and pharmaceutically ...
|
|
WO/2012/173504A2 |
The present invention refers to the method of synthesis of the substituted azetidinones of formula 1. In particular, the present invention refers to the method of synthesis of (3R,4S)-1-(4-fluorophenyl)-3-[(3´S)-3-(4-fluorophenyl)-3-hy
...
|
|
WO/2012/155932A1 |
The present invention provides an improved process for the preparation of compound of Formula II, which is a key intermediate for the preparation of Ezetimibe, through stereoselective addition of an organometallic reagent to novel aldehy...
|
|
WO/2012/157504A1 |
Provided are: a β-lactam compound in which two adjacent carbon atoms present in a β-lactam ring are asymmetric carbon atoms respectively having four different substituents; a method for producing the β-lactam compound; a production in...
|
|
WO/2012/143337A1 |
The present invention relates to novel substituted phenoxyethylamine derivatives, useful as modulators of cortical and basal ganglia dopaminergic and N-methyl-D-aspartate (NMDA) receptor-mediated glutamatergic neurotransmission. In other...
|
|
WO/2012/142268A1 |
The present invention relates to novel phenyl bicyclic methyl azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate rece...
|
|
WO/2012/124696A1 |
[Problem] To provide a compound which is useful as an active ingredient of a pharmaceutical composition, especially of a pharmaceutical composition for the prophylaxis and/or treatment of VAP-1 associated diseases. [Solution] As a result...
|
|
WO/2012/108397A1 |
The purpose of the present invention is to provide a novel cationic lipid which forms lipid particles. Provided are: a compound represented by formula (I); lipid particles which contain the compound; nucleic acid lipid particles which co...
|
|
WO/2012/103456A2 |
Provided herein are polycyclic β-lactam compounds, compositions thereof and methods for the treatment and prevention of diseases such as cancer, including pancreatic cancer and pancreatic cancers resistant to mainline chemotherapeutic a...
|
|
WO/2012/098033A1 |
Compounds are disclosed that have a formula represented by the following: These compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including h...
|
|
WO/2012/091010A1 |
The purpose of the present invention is to provide: a compound which has a MGAT inhibitory effect and is useful as a pharmaceutical product, or a physiologically acceptable salt of the compound; and a pharmaceutical composition which con...
|
|
WO/2012/083436A1 |
The invention provides methods of making and using compounds of the formula (I) or a pharmaceutically acceptable salt thereof; wherein n is an integer between 1 and 2 inclusively; m is an integer between 0 and 2 inclusively; X is selecte...
|
|
WO/2012/084711A1 |
The present invention relates to novel N-substituted azetidine derivatives < of the formula (I); wherein SERMF is a Selective Estrogen Receptor Modilator fragment; X is no atom, O, S, CH2, carbonyl, N-R5; R1 is H, (C1 -8)alkyl, (C3-8)cyc...
|
|
WO/2012/076030A1 |
The present invention provides an improved process for preparing (3R, 4S)-4-(4- (benzyloxy)phenyl)-1-(4-fluorophenyl)-3-(3-(4-fluorophenyl)-
3-oxopropyl)azetidin-2-one, which is a key intermediate for the preparation of Ezetimibe, and in...
|
|
WO/2012/074926A1 |
The present invention relates to novel azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
|
|
WO/2012/074780A1 |
The present invention relates to novel oxime azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
|
|
WO/2012/074469A1 |
The invention relates to compounds according to Formula (I): or a pharmaceutically acceptable salt thereof, wherein m, n, R1, R2, R3, R4, R5, x and y are as defined herein. Compounds according to Formula (I) are pharmacologically effecti...
|
|
WO/2012/069566A1 |
The invention relates to a process for preparing an N-heterocycle, comprising a step of bringing a compound comprising at least two nitrile functions into contact with a siloxane hydride or silane hydride and a metal oxide or metal amide...
|
|
WO/2012/063085A2 |
The present invention relates to derivatives of known active pharmaceutical compounds. These derivatives are differentiated from the parent active compound by virtue of being redox derivatives of the active compound. This means that one ...
|
